JAMES ROSSI: Open Payments
NPI 1659802924 · LEXINGTON, KY. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$388 in 22 payments from 15 companies in 2025. Trend: 2023 $387 · 2024 $489 · 2025 $388
Food & beverage: $376Education: $12
| Company | Payments | Amount |
|---|---|---|
| Lilly USA, LLC | 4 | $70 |
| Gilead Sciences, Inc. | 3 | $50 |
| PFIZER INC. | 2 | $41 |
| Novo Nordisk Inc | 2 | $32 |
| Verity Pharmaceuticals Inc. | 1 | $26 |
| Takeda Pharmaceuticals U.S.A., Inc. | 1 | $21 |
| Agios Pharmaceuticals, Inc. | 1 | $21 |
| Daiichi Sankyo Inc. | 1 | $18 |
| Vanda Pharmaceuticals Inc. | 1 | $17 |
| Astellas Pharma US Inc | 1 | $17 |
Products named: MOUNJARO, Tlando, PAXLOVID, VPRIV, PYRUKYND, PREVNAR 20, INJECTAFER, FANAPT.
Industry payments across KY — which companies pay providers there.
